Peripheral Vascular Diseases
📧 Sign up to get email alerts when something new happens for Peripheral Vascular Diseases.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Hexal (clopidogrel) — Acino Pharma GmbH
Clopidogrel Hexal (clopidogrel) has been withdrawn from the market by Acino Pharma GmbH.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Acino Pharma GmbH (clopidogrel) — Acino Pharma GmbH
Clopidogrel product from Acino Pharma GmbH has been withdrawn from the market.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Acino Pharma (clopidogrel) — Acino Pharma GmbH
The EMA withdrew Clopidogrel Acino Pharma (clopidogrel) from use; linked to peripheral vascular diseases, stroke, and myocardial infarction …
-
EMA withdrawal · 2011-10-26EMA Withdrawn: Clopidogrel Sandoz (clopidogrel) — Acino Pharma GmbH
The EMA indicates withdrawal of Clopidogrel Sandoz (clopidogrel) by Acino Pharma GmbH.
-
EMA withdrawal · 2010-01-26EMA Withdrawn: Clopidogrel BMS (clopidogrel (as hydrogen sulfate)) — Bristol-Myers Squibb Pharma EEIG
The EMA information indicates that the clopidogrel BMS product (clopidogrel as hydrogen sulfate) has been withdrawn from the market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2008-05-27EMA Application withdrawn: DuoCover (clopidogrel;acetylsalicylic acid) — Bristol Myers Squibb Pharma EEIG
EMA withdrew the application for DuoCover (clopidogrel and acetylsalicylic acid) from Bristol Myers Squibb Pharma EEIG.
-
EMA withdrawal · 2008-05-27EMA Application withdrawn: DuoPlavin (clopidogrel;acetylsalicylic acid) — Sanofi Pharma Bristol-Myers Squibb
EMA withdrew the application for DuoPlavin (clopidogrel and acetylsalicylic acid) by Sanofi Pharma Bristol-Myers Squibb.